Quest Diagnostics (DGX) Competitors $189.15 +2.33 (+1.25%) As of 12:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DGX vs. HSIC, MEDP, AMN, LH, DVA, CHE, CRVL, MD, CCRN, and EHCShould you be buying Quest Diagnostics stock or one of its competitors? The main competitors of Quest Diagnostics include Henry Schein (HSIC), Medpace (MEDP), AMN Healthcare Services (AMN), Labcorp (LH), DaVita (DVA), Chemed (CHE), CorVel (CRVL), Pediatrix Medical Group (MD), Cross Country Healthcare (CCRN), and Encompass Health (EHC). Quest Diagnostics vs. Its Competitors Henry Schein Medpace AMN Healthcare Services Labcorp DaVita Chemed CorVel Pediatrix Medical Group Cross Country Healthcare Encompass Health Henry Schein (NASDAQ:HSIC) and Quest Diagnostics (NYSE:DGX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk. Which has more risk & volatility, HSIC or DGX? Henry Schein has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Do insiders and institutionals have more ownership in HSIC or DGX? 96.6% of Henry Schein shares are owned by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are owned by institutional investors. 1.1% of Henry Schein shares are owned by company insiders. Comparatively, 8.2% of Quest Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher valuation & earnings, HSIC or DGX? Quest Diagnostics has lower revenue, but higher earnings than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHenry Schein$12.67B0.60$390M$3.1020.37Quest Diagnostics$9.87B2.14$871M$8.3522.65 Does the media favor HSIC or DGX? In the previous week, Henry Schein had 6 more articles in the media than Quest Diagnostics. MarketBeat recorded 30 mentions for Henry Schein and 24 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.07 beat Henry Schein's score of 0.51 indicating that Quest Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Henry Schein 10 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Quest Diagnostics 17 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend HSIC or DGX? Henry Schein presently has a consensus target price of $76.67, indicating a potential upside of 21.43%. Quest Diagnostics has a consensus target price of $189.06, indicating a potential downside of 0.04%. Given Henry Schein's higher probable upside, equities research analysts plainly believe Henry Schein is more favorable than Quest Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Henry Schein 0 Sell rating(s) 8 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.38Quest Diagnostics 0 Sell rating(s) 10 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.53 Is HSIC or DGX more profitable? Quest Diagnostics has a net margin of 9.01% compared to Henry Schein's net margin of 3.05%. Quest Diagnostics' return on equity of 15.24% beat Henry Schein's return on equity.Company Net Margins Return on Equity Return on Assets Henry Schein3.05% 14.36% 5.52% Quest Diagnostics 9.01%15.24%6.64% SummaryQuest Diagnostics beats Henry Schein on 12 of the 17 factors compared between the two stocks. Get Quest Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DGX vs. The Competition Export to ExcelMetricQuest DiagnosticsMED IndustryMedical SectorNYSE ExchangeMarket Cap$21.16B$4.30B$6.09B$21.70BDividend Yield1.71%1.24%5.73%3.59%P/E Ratio22.6630.2884.2232.41Price / Sales2.14257.65606.1579.86Price / Cash13.8728.4037.8624.53Price / Book3.084.7012.304.58Net Income$871M$197.51M$3.32B$1.01B7 Day Performance2.64%4.30%0.42%1.22%1 Month Performance3.86%6.07%7.68%-0.60%1 Year Performance27.00%26.98%71.71%10.39% Quest Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DGXQuest Diagnostics4.7879 of 5 stars$189.15+1.2%$189.060.0%+25.3%$21.16B$9.87B22.6656,000Positive NewsUpcoming EarningsAnalyst ForecastHSICHenry Schein4.1554 of 5 stars$63.00-0.3%$76.67+21.7%-13.5%$7.64B$12.77B20.3225,000Trending NewsAnalyst RevisionMEDPMedpace4.4295 of 5 stars$527.40+5.2%$422.27-19.9%+50.4%$14.82B$2.23B39.215,900Upcoming EarningsAnalyst ForecastAMNAMN Healthcare Services4.4437 of 5 stars$19.14+5.4%$23.08+20.6%-51.0%$733.45M$2.98B-2.462,968Trending NewsShort Interest ↓Analyst RevisionLHLabcorp4.4669 of 5 stars$276.37-0.5%$292.00+5.7%+30.8%$22.97B$13.01B30.5070,000Positive NewsAnalyst ForecastDVADaVita4.8251 of 5 stars$123.89-0.1%$155.25+25.3%-24.0%$8.86B$13.16B12.1876,000Analyst ForecastCHEChemed4.9817 of 5 stars$429.20-0.2%$578.50+34.8%-29.2%$6.25B$2.43B22.0715,695Positive NewsCRVLCorVel1.0832 of 5 stars$71.41-1.7%N/A-34.7%$3.66B$895.59M36.815,075News CoverageAnalyst ForecastMDPediatrix Medical Group1.8146 of 5 stars$16.06+1.6%$16.79+4.5%+28.0%$1.40B$2.01B12.454,305Analyst ForecastCCRNCross Country Healthcare3.7057 of 5 stars$12.50+7.9%$17.93+43.4%+3.6%$409.50M$1.34B-48.088,205EHCEncompass Health4.8131 of 5 stars$121.35-0.7%$139.86+15.2%+26.3%$12.22B$5.67B23.7540,000Positive News Related Companies and Tools Related Companies Henry Schein Alternatives Medpace Alternatives AMN Healthcare Services Alternatives Labcorp Alternatives DaVita Alternatives Chemed Alternatives CorVel Alternatives Pediatrix Medical Group Alternatives Cross Country Healthcare Alternatives Encompass Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DGX) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quest Diagnostics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Quest Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
